Phenibut

A Soviet-developed anti-anxiety compound — a GABA analog that crosses the blood-brain barrier and acts mainly on GABA-B receptors (the same receptor family as baclofen). Sold online as a "nootropic" for anxiety and sleep.

Phenibut is GABA with a phenyl ring added, a modification that lets it cross into the brain in a way GABA itself cannot. It has reported activity at GABA-B receptors — the target baclofen hits — and at the alpha2-delta subunit of voltage-gated calcium channels, the target gabapentin and pregabalin hit. How much each contributes to its effects in people, or to withdrawal, is genuinely uncertain; the receptor work is binding assays and animal studies. What is not uncertain is that it belongs pharmacologically alongside baclofen rather than alongside a supplement.

Human evidence is thin and mostly Russian: small trials for anxiety and asthenia decades old. Western clinical literature about phenibut is dominated not by efficacy studies but by case reports of dependence and withdrawal — which is itself the evidence picture worth knowing.

• Developed in the Soviet Union in the 1960s and still a prescription medicine in some countries for anxiety and sleep. The clinical literature behind it is old, largely Russian-language and does not meet modern trial standards.
• There is essentially no modern randomised evidence in the doses and patterns people actually use it in.
• What does exist in the Western literature is a substantial dependence and withdrawal case literature — poison-centre reports, emergency presentations and case series describing agitation, hallucinations, psychosis and seizures on abrupt cessation.
• Withdrawal has repeatedly required hospital admission and benzodiazepine or baclofen management. Several published cases involved people who had been using it as an over-the-counter supplement and did not know it was capable of this.
• Dependence and withdrawal have been reported after as little as one week of use. How often tolerance develops, and how quickly it usually does, are not established — the literature is heterogeneous case reports, not incidence data. FDA warned in 2026 that addiction may develop after only a few uses.

It is sold as a dietary supplement in some markets despite being a prescription medicine elsewhere and having no legitimate supplement status, and that mismatch is the source of most of the harm — people take it without knowing it belongs in the same conversation as baclofen. FDA's 2026 alert names poor balance, fatigue, reduced or lost consciousness, and potentially life-threatening complications when combined with other substances.

The standout risk in this entire list for dependence: tolerance builds within weeks of regular use, and withdrawal — documented in numerous case reports — can be severe (rebound anxiety, insomnia, agitation, psychosis in the worst cases) and medically complicated. Combining with alcohol or other depressants adds respiratory-depression risk. Poison-control calls for phenibut rose sharply through the 2010s.

• Anyone with a history of substance dependence
• Anyone drinking alcohol or taking any other sedative
• Anyone using it for anxiety in place of actual treatment
• Anyone who cannot commit to keeping it to occasional use, which most people cannot
• Anyone pregnant or breastfeeding

• Alcohol — dangerous additive central nervous system and respiratory depression, and present in a large share of serious cases.
• Benzodiazepines, opioids, and any sedative — the same additive depression risk.
• Baclofen and gabapentinoids, which share its targets directly.
• Antihistamines and sleep aids, commonly stacked without realising they compound it.

• Frequency of use, honestly recorded. Daily use is the single strongest predictor of dependence and people consistently underestimate their own.
• Escalating dose, which is the earliest reliable warning sign.
• Sleep and anxiety on days off — rebound worse than baseline means dependence is established.
• Anyone using it regularly needs a clinician or poison centre involved before stopping, not a stop date.

This is the section that matters most for this compound. After regular use, stopping abruptly can produce severe withdrawal — agitation, insomnia, tremor, hallucinations, psychosis and seizures — with published cases requiring hospital admission. Reports are too heterogeneous to say which treatments work, so no specific approach is described here on purpose. It is not a compound to quit cold on your own. Anyone using it regularly needs a clinician or a poison centre involved, and needs to say exactly what it is, because "a GABA supplement" will not communicate the risk to someone who has never seen a case.

US: unscheduled federally but NOT a lawful dietary ingredient (FDA has warned sellers); banned in a few states. Prescription drug in Russia; controlled in Australia and Hungary.

Papers about this compound, not proof of the claims above. A title says what was studied, which is sometimes a negative result or a different question entirely.

• A systematic review of phenibut withdrawal focusing on complications, therapeutic approaches, and single substance versus polysubstance withdrawal
  Clin Toxicol (Phila), 2023
• Safety and Tolerability of the Anxiolytic and Nootropic Drug Phenibut: A Systematic Review of Clinical Trials and Case Reports
  Pharmacopsychiatry, 2020
• Clinical Presentations and Treatment of Phenibut Toxicity and Withdrawal: A Systematic Literature Review
  J Addict Med, 2023

• Phenibut: A drug with one too many "buts"Basic Clin Pharmacol Toxicol · 2024
• Phenibut: Review and Pharmacologic Approaches to Treating WithdrawalJ Clin Pharmacol · 2024
• A Systematic Review of Phenibut WithdrawalsCureus · 2024
• Phenibut (β-Phenyl-γ-Aminobutyric Acid): an Easily Obtainable "Dietary Supplement" With Propensities for Physical Dependence and AddictionCurr Psychiatry Rep · 2019
• Clinical Presentations and Treatment of Phenibut Toxicity and Withdrawal: A Systematic Literature ReviewJ Addict Med · 2023
• A systematic review of phenibut withdrawal focusing on complications, therapeutic approaches, and single substance versus polysubstance withdrawalClin Toxicol (Phila) · 2023
• Phenibut overdoseAm J Emerg Med · 2017
• Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drugCNS Drug Rev · 2001
• Acute phenibut withdrawal: A comprehensive literature review and illustrative case reportBosn J Basic Med Sci · 2019
• Quantity of phenibut in dietary supplements before and after FDA warningsClin Toxicol (Phila) · 2022
• Phenibut withdrawal management in a neonatePediatr Neonatol · 2022
• Phenibut Dependence and WithdrawalPrim Care Companion CNS Disord · 2021